GI
RNA

GAMMA Investing’s Atrium Therapeutics RNA Stock Holding History

GAMMA Investing’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62K Sell
195
-140
-42% -$1.83K ﹤0.01% 3680
2026
Q1 		$4.48K Buy
+335
New +$4.71K ﹤0.01% 3400

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

GAMMA Investing's RNA Position: Q2 2026 in Review

GAMMA Investing reduced its Atrium Therapeutics (RNA) stake by 42% in Q2 2026, selling an estimated $1.83K and leaving 195 shares worth $2.62K. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

GAMMA Investing first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.48K in Q1 2026. 8 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • GAMMA Investing held 195 shares of Atrium Therapeutics worth $2.62K as of Q2 2026.
  • GAMMA Investing sold 140 Atrium Therapeutics shares in Q2 2026, an estimated $1.83K.
  • Atrium Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3680 holding.
  • GAMMA Investing first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GAMMA Investing's Atrium Therapeutics position peaked at $4.48K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.